All in: Gilead maps a $3.15B gene edit­ing al­liance with Sang­amo for off-the-shelf CAR-T drugs

In a block­buster en­dorse­ment of its gene-edit­ing tech­nol­o­gy, Gilead $GILD has tapped Sang­amo’s zinc fin­ger nu­cle­ase ap­proach to tai­lor­ing its next-gen pro­grams for off-the-shelf as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER